首页 | 本学科首页   官方微博 | 高级检索  
     

醋柳黄酮对高血压游离钙浓度及胰岛素敏感性的影响
引用本文:龚铭 廖晓阳. 醋柳黄酮对高血压游离钙浓度及胰岛素敏感性的影响[J]. 现代中西医结合杂志, 2000, 9(14): 1303-1307
作者姓名:龚铭 廖晓阳
作者单位:[1]浙江省瑞安市人民医院内二科 [2]华西医科大学第一附属医院
摘    要:目的 :探讨醋柳黄酮的降压机理以及对高血压患者胰岛素敏感性的影响。方法 :笔者以尼群地平作为对照 ,将69例高血压患者随机分为 :1醋柳黄酮组 ( 3 5例 ) ;2尼群地平组 ( 3 4例 ) ,进行了为期 8周的降压治疗 ,测定了治疗前后患者的收缩压、舒张压、红细胞胞浆浆游离钙浓度、空腹血糖和血浆胰岛素浓度 ,并以空腹血糖与血浆胰岛素浓度乘积的倒数作为胰岛素敏感性指数。结果 :经过 8周治疗后发现 ,1两组的收缩压和舒张压均较治疗前明显下降 ( P<0 .0 5 ) ,醋柳黄酮组和尼群地平组的有效率分别为 74.2 8和 85 .2 9 ,两组之间无明显差异 ( P>0 .0 5 ) ,但醋柳黄酮组的降压显效时间晚于尼群地平组 ;2两组的红细胞胞浆游离钙浓度较治疗前均有显著下降 ( P<0 .0 5 ) ,但醋柳黄酮组红细胞胞游离钙浓度降低幅度明显小于尼群地平组 ( P<0 .0 5 ) ;3醋柳黄酮组治疗后空腹血糖浓度明显降低 ( P<0 .0 5 ) ,血浆胰岛素浓度无明显变化 ( P>0 .0 5 ) ,胰岛素敏感性改善 ( P<0 .0 5 ) ;而尼群地平组空腹血糖浓度、血浆胰岛素浓度和胰岛素敏感性均无明显变化 ( P>0 .0 5 )。结论 :醋柳黄酮是一种有效的降压药物 ,醋柳黄酮还能够改善高血压患者的胰岛素敏感性 ,可能对高血压患者的靶器官具有一定的保护作用。

关 键 词:醋柳黄酮  高血压  游离钙浓度  胰岛敏感性

The effect of total hippopae rhamnoides L on intraerythrocytic free calcium concentration and insulin sensitivity of hypertensive patients
Gong Ming Ruian People's Hospital,Zhejiang Province, Liao Xiaoyang,Zhang Maoshun,Wang Jialiang,et al NO. Hospital of West China University of Medical Scienes,Sichuan Province. The effect of total hippopae rhamnoides L on intraerythrocytic free calcium concentration and insulin sensitivity of hypertensive patients[J]. Modern Journal of Integrated Chinese Traditional and Western Medicine, 2000, 9(14): 1303-1307
Authors:Gong Ming Ruian People's Hospital  Zhejiang Province   Liao Xiaoyang  Zhang Maoshun  Wang Jialiang  et al NO. Hospital of West China University of Medical Scienes  Sichuan Province
Affiliation:Gong Ming Ruian People's Hospital,Zhejiang Province,325200 Liao Xiaoyang,Zhang Maoshun,Wang Jialiang,et al NO.1 Hospital of West China University of Medical Scienes,Sichuan Province,610041
Abstract:Objective: The study investigated the antihypertensive mechanism of total hippopae rhamnoides L(THRL) and its effecton insulin sensitivity of hypertensive patients. Methods: The authors took nitrendipine as control. Hypertensive patients (n=69) were randomly divided into two groups: ①totl hippopae rhamnoides L group (n=35); ②nitrendipine group (n=34). They had received antihypertensive treatment with total hippopae rhamnoides L and nitendipine for 8 weeks respectively. The following tests were measured before and after treatment including blood pressure, intraerythrocytic free calcium concentration, fasting blood plasma glucose (FBG) and fasting blood plasma insulin (FBI) concentration. The reverse of fasting blood plasma glucose and insulin concentration product was used as insulin sensitivity index (ISI). Results: It was found, ①Both systloin and diastloin blood pressure were reduved significantly in two groups (P<0.05).The effective rate of antihypertensive action of total hippopae rhamnoides L and nitrendipine was 74.28% and 85.29% respectively. It's without significant difference between the two groups (P>0.05), but the time that antihypertensive effect occurred in total hippopae rhamnoides L group was later than that of nitrendipine group; ②Intraerythrocytic free calcium concentration was decreased significantly in both groups(P<0.05). but the decreasing degree of intraerythrolytic free calciurn consentcation in total hippopae rhamnoides L group was low markedly as compared with nitrendipine group; ③In nitrendipine group, fasting blood plasma glucose, insulin and insulin sensitivity did not change markedly. But in total hippopae rhmniodes L group, fasting blood plasma glucose was reduced markedly (P<0.05) and insulin sensitivity was improved significantly (P<0.05) and fasting blood plasma insulin did not alter markedly (P>0.05). Conclusion: All the above results show that the total hippopae rhamnoides L is a effective antihypertensive drug. Total hippopae rhamnoides L also can improve the insulin sensitvity of hypertensive patients and probably play certein role in protecting target organs of hypertensive patients.
Keywords:total hippopae rhamnoides L hypertension free calcium concentration insulin sensitivity
本文献已被 CNKI 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号